ICOS Quartalszahlen - 500 Beiträge pro Seite

[Snoopy28]

Gestern abend sind noch Quartalszahlen veröffentlicht worden. Hat jemand eine Ahnung wie sie waren??? Wo kann man so etwas eigentlich am schnellsten herausfinden??

[Langoustier]

Hallo Snoopy,
schau doch mal unter
http://www.nasdaq.com/asp/quotes_news.asp?symbol=ICOS%60&sel…
nach!
Hätte es gerne hier rein gestellt, ist aber von der Formatierung unter aller Sau (Spalten!!), ist mir zuviel action...
Gruß Langoustier

[Langoustier]

Nachtrag:

BOTHELL, Wash.--(BUSINESS WIRE)--Jan. 25, 2001--ICOS Corporation (Nasdaq:ICOS) (the "Company") today released its financial results for the fourth quarter and year ended December 31, 2000, reviewed the progress over the last twelve months and summarized upcoming clinical events.

During 2000 the Company expanded its pipeline and gained critical information from clinical trials. The formation of a collaboration with Texas Biotechnology Corporation positioned ICOS with potential treatments for cardiovascular diseases with two endothelin receptor antagonists, sitaxsentan and TBC3711, both clinical-stage product candidates. Separately ICOS established an exclusive license with Stanford University on polyphosphate kinase (PPK) technology. Inhibitors of PPK could offer a new approach to treating antibiotic-resistant bacterial strains, a serious medical challenge.

Over the last twelve months, ICOS, with its joint venture partner Eli Lilly and Company, continued to acquire extensive clinical data on Cialis in erectile dysfunction for the New Drug Application submission scheduled for 2001. Phase 2 clinical results were presented at several medical meetings in the United States and internationally during the year. Clinical data from a Phase 2 trial with Pafase in patients with severe sepsis and severe multiple traumatic injuries were presented at the International Symposium on Intensive Care and Emergency Medicine. The outcome of the study and input from leaders in the treatment of sepsis support the Company`s plans to begin a multi-national Phase 3 clinical study with severe sepsis patients. The breadth of the Company`s clinical program will expand further this year with the initiation of trials with two new compounds, IC485, a PDE4 inhibitor and IC747, a LFA-1 antagonist.

"ICOS is poised for several major events in 2001. As a product-driven company, it is important for us to have diversity in our disease indications and a pipeline that is balanced with late and early stage product candidates," stated Paul Clark, Chairman and Chief Executive Officer. "Our commitment to world class research and development should provide follow-on products that offer additional opportunities."

For the fourth quarter of 2000, ICOS reported a net loss of $10.6 million ($0.22 per share), compared to net income of $4.3 million ($0.09 per diluted share) for the fourth quarter of 1999.

Total revenues were $32.2 million for the fourth quarter of 2000, compared to $29.8 million for the fourth quarter of 1999. Fourth quarter 2000 cost reimbursement revenues from collaborative research and development activities, were $15.7 million, including $6.7 million from Lilly ICOS LLC ("Lilly ICOS"), $4.6 million from Suncos Corporation ("Suncos"), $2.6 million from ICOS Clinical Partners, L.P. ("ICOS Clinical Partners") and $1.8 million from ICOS-Texas Biotechnology L.P. ("ICOS-TBC"). Fourth quarter 1999 cost reimbursement revenues were $14.8 million, including $5.8 million from Lilly ICOS, $3.3 million from Suncos, and $5.7 million from ICOS Clinical Partners.

In the 2000 fourth quarter, the Company adopted the provisions of Securities and Exchange Commission Staff Accounting Bulletin No. 101, as amended ("SAB 101"), "Revenue Recognition in Financial Statements." Pursuant to SAB 101, technology license fees and milestone payments, for product candidates where the Company is providing continuing services related to product development, are deferred and recognized as revenue over the product development period, based on estimated total development costs. Previously, those license fees and milestone payments were recognized as revenue when received. For the quarter ended December 31, 2000, the Company recognized as revenue $16.1 million of the $63.1 million of deferred revenue that was recorded upon adoption of SAB 101 effective January 1, 2000. The $16.1 million decreased the quarterly loss before the cumulative effect of the accounting change by 34 cents per share. In the 1999 fourth quarter, the Company recognized as revenue $15.0 million of milestone payments upon receipt.

Total operating expenses were $26.2 million in the fourth quarter of 2000, compared to $25.0 million in the 1999 fourth quarter. Research and development expense totaled $23.8 million in the 2000 quarter compared to $23.3 million in the 1999 quarter. The increase in research and development expense reflects the progression of clinical trials for Cialis(TM), Pafase(R) and sitaxsentan and the expansion of other product development efforts, partially offset by the discontinuation of certain clinical programs that were ongoing during 1999.

In the fourth quarter of 2000, the Company recognized $18.1 million of losses related to its equity interests in affiliates, compared to $1.9 million of affiliate losses in the fourth quarter of 1999. The increase primarily reflects the Company`s share of operating losses of Lilly ICOS. Since the third quarter of 2000, the Company has recognized its share of Lilly ICOS` losses because it will be funding its proportionate share of Lilly ICOS operations. Previously, Eli Lilly and Company funded 100% of Lilly ICOS` operations.

For the year ended December 31, 2000, ICOS reported a net loss of $97.9 million ($2.11 per share), compared to a net loss of $33.2 million ($0.76 per share) in 1999. The results for 2000 include a $63.1 million charge ($1.36 per share) for the cumulative effect on prior years of adopting SAB 101 effective January 1, 2000. In 2000, the Company recognized $42.9 million of the $63.1 million of technology license revenue that was deferred upon adoption of SAB 101, which decreased the loss before the cumulative effect of the accounting change by 93 cents per share. Accordingly, adoption of SAB 101 had the effect of increasing the net loss per share for 2000, from $1.68 to the reported $2.11, an increase in the per share net loss of 43 cents.

Total revenues were $90.7 million for the year ended December 31, 2000, compared to $79.6 million for the year ended December 31,1999. For the year 2000, cost reimbursement revenues from collaborative research and development activities, were $47.4 million, including $19.9 million from Lilly ICOS, $15.2 million from Suncos, $9.5 million from ICOS Clinical Partners, and $2.8 million from ICOS-TBC. For the year ended December 31, 1999, cost reimbursement revenues were $64.1 million, including $19.9 million from Lilly ICOS, $25.1 million from Suncos and $19.1 million from ICOS Clinical Partners.

Total operating expenses for 2000 were $94.0 million, compared to $105.8 million for 1999. Research and development expense totaled $87.4 million during the latest year, compared to $100.5 million in 1999. The decrease in research and development expense was primarily due to the discontinuation of certain clinical programs as well as completion, in 2000, of multiple Pafase(R) clinical studies that were ongoing during 1999.

During 2000, the Company recognized $37.0 million of losses primarily related to its equity interests in the Lilly ICOS, Suncos and ICOS-TBC collaborations. During 1999, the Company recognized $12.0 million of losses primarily related to its equity interest in Suncos.

At December 31, 2000, the Company had cash, cash equivalents, investment securities available for sale and interest receivable of $229.4 million, including the approximately $181 million net proceeds from the public offering of 5.2 million shares of the Company`s common stock in December 2000.

The Company`s results of operations will vary significantly from quarter to quarter. Results will depend on, among other factors, the timing of revenues and expenses, the establishment of collaborative research agreements, and the progress of the Company`s research and development efforts, including the achievement of milestones under new and existing licensing and collaborative agreements.

ICOS is a product-driven company that has expertise in both protein-based and small molecule therapeutics. The Company combines capabilities in molecular, cellular and structural biology, high throughput drug screening, medicinal chemistry and genomics to develop highly innovative products with significant commercial potential. The Company applies its integrated approach to specific target areas where it has expertise. ICOS believes this strategy increases the chances of successfully developing commercial products. These target areas include erectile dysfunction, female sexual dysfunction, sepsis, pulmonary hypertension and other cardiovascular diseases. -- Company management will host a conference call today at 1:30 p.m. PST (4:30 p.m. EST). The conference call, with reservation number 17262449, can be accessed live by phone at 1:30 p.m. PST at 415/537-1857 or in a replay for 24 hours at 800/633-8284 from within the U.S. or 858/812-6440 from outside the U.S. Additionally, a webcast is available live and archived until January 29, by going to ICOS` website at www.icos.com. For additional information on ICOS, including previous press releases, see www.icos.com on the Internet.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve risks and uncertainties that could cause the Company`s results and the timing of certain events to differ materially from those discussed in the forward-looking statements, including risks associated with clinical development, regulatory approvals, product commercialization, intellectual property claims and litigation and other risks detailed in the Company`s latest registration statement on Form S-3, its latest Annual Report on Form 10-K and its other public filings filed with the Securities and Exchange Commission.

[Langoustier]

Kurz und knapp ein letzter Nachtrag:

ICOS reports smaller-than-expected Q4 loss

BOTHELL, Wash., Jan 25 (Reuters) - Drug developer ICOS Corp. <ICOS.O> reported on Thursday a fourth-quarter loss that was much smaller than Wall Street estimates.

For the fourth quarter of 2000, ICOS reported a net loss of $10.6 million, or 22 cents a share, on revenues of $32.2 million, compared with a net income of $4.3 million, or 9 cents a share, on revenues of $29.8 million for the fourth quarter of 1999.

Wall Street analysts on average had expected the company to post a loss of 56 cents a share for the quarter.

Bothell, Wash.-based ICOS and joint venture partner Eli Lilly and Co. <LLY.N> are developing a new anti-impotence drug called Cialis, a potential competitor to Pfizer Inc.`s <PFE.N> blockbuster drug Viagra if it succeeds in Phase III trials now under way.

((--Los Angeles bureau + 1 213 380 2014))

REUTERS

Rtr 15:33 01-25-01

[Snoopy28]

Dann ist der Verlust mehr als die Hälfte weniger als erwartet? habe ich das richtig gelesen oder?
Cialis ist dann jetzt in Phase 3. Das muß doch endlich voll die Zündung nach oben sein, hoffen wir es mal zumindest.

[Langoustier]

...schaun wer mal! Ich teile zumindest Deine Hoffnungen!!!
Gruß Langoustier

[Snoopy28]

Icos hält sich echt stabil in letzter Zeit, gab es in den letzten Woche einige News??

[okujawa]

Es ist recht ruhig um Icos geworden aber, sie hält sich wirklich gut.Ist zur Zeit mein "bestes Pferd im Stall", voll im grünen Bereich ....und das will was heissen.
cu
ok